Android app on Google Play

Opko Health (OPK) Acquires Two New Phase 3 Products

January 8, 2013 5:31 PM EST Send to a Friend
Opko Health (NYSE: OPK) entered into a definitive agreement to acquire Cytochroma Inc. (Markham, Canada) whose lead products, both in phase 3 clinical trials, are Replidea™ (coded CTAP101 Capsules), a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen™, a non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients.

You May Also Be Interested In

Related Categories

FDA, Mergers and Acquisitions

Add Your Comment